[1] Arber DA, Orazi A, Hasserjian R, et al.he 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood,2016, 127(20):2391-2405.
[2] Bennett JM, Catovsky D, Daniel MT, et al.Proposals for the classification of the myelodysplastic syndromes[J]. Br J Haematol,1982,51(2):189-199.
[3] Guru Murthy GS, Dhakal I, Mehta P.Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States[J]. Leuk Lymphoma,2017,58(7):1648-1654.
[4] Srour SA, Devesa SS, Morton LM, et al.Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12[J]. Br J Haematol,2016,174(3):382-396.
[5] Solary E, Itzykson R.How I treat chronic myelomonocy-tic leukemia[J]. Blood,2017,130(2):126-136.
[6] Patnaik MM, Tefferi A.Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management[J]. Am J Hematol,2016,91(6):631-642.
[7] Pophali PA, Patnaik MM.The role of new tyrosine kinase inhibitors in chronic myeloid leukemia[J]. Cancer J,2016, 22(1):40-50.
[8] Patnaik MM, Lasho TL, Finke CM, et al.Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis[J]. Am J Hematol,2016,91(3):E12-E14.
[9] Bain BJ.What is a promonocyte?[J]. Am J Hematol,2013,88(10):919.
[10] Tang G, Zhang L, Fu B, et al.Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution[J]. Am J Hematol,2014, 89(8):813-818.
[11] Such E, Cervera J, Costa D, et al.Cytogenetic risk stratification in chronic myelomonocytic leukemia[J]. Haematologica,2011,96(3):375-383.
[12] Patnaik MM, Itzykson R, Lasho TL, et al.ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients[J]. Leukemia,2014,28(11):2206-2212.
[13] Jankowska AM, Makishima H, Tiu RV, et al.Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A[J]. Blood,2011,118(14):3932-3941.
[14] Smith AE, Mohamedali AM, Kulasekararaj A, et al.Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value[J]. Blood,2010,116(19):3923-3932.
[15] Itzykson R, Solary E.An evolutionary perspective on chronic myelomonocytic leukemia[J]. Leukemia,2013,27(7):1441-1450.
[16] Patnaik MM, Tefferi A.Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia[J]. Blood Cancer J,2016,6:e393.
[17] Talati C, Zhang L, Shaheen G, et al. Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis[J]. Blood,2017 Mar 30,129(13):1881-1883.
[18] Selimoglu-Buet D, Wagner-Ballon O, Saada V, et al.Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia[J]. Blood,2015,125(23):3618-3626.
[19] Vardiman JW, Thiele J, Arber DA, et al.The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes[J]. Blood,2009,114(5):937-951.
[20] Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System[J]. Cancer,2008,113(6):1351-1361.
[21] Such E, Germing U, Malcovati L, et al.Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia[J]. Blood,2013,121(15):3005-3015.
[22] Patnaik MM, Padron E, LaBorde RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes[J]. Leukemia,2013,27(7):1504-1510.
[23] Onida F, Barosi G, Leone G, et al. Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups[J]. Haematologica,2013 Sep,98(9):1344-1352.
[24] Barosi G, Birgegard G, Finazzi G, et al.A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European Leukemia Net(ELN) consensus process[J]. Br J Haematol,2010,148(6):961-963.
